The big unknown is what deal we have with American Regent. With a 3 year limit it's most likely a simple percentage split. I would think Nader would hold out for 50% but it's unknown. Overseas distribution is going to come down to whether it's for a single indication or all indications going forward. With an already approved drug though we will be coming into any negotiations with a strong hand.